GovChime
Notice ID: 64475df9ce3c4c9590e2b3a925cb1167Combined Synopsis/Solicitation

SARS-CoV2 3CL protease cell-based assay development for drug screening

Archived on June 26, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
11:59 AM UTC−04:00
Posted
June 5, 2020
Notice type
Combined Synopsis/Solicitation
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
541380: Testing Laboratories and Services
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIDA
Last updated
Sep 9, 2025

Identifiers

Solicitation number
75N95020Q00142
Notice ID
64475df9ce3c4c9590e2b3a925cb1167

Description

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) requires SARS-CoV2 3CL protease cell-based assay development for drug screening to support efforts related to COVID-19. This requirement includes assay development, stable cell line generation and selection by luciferase activity as outlined in the Statement of Work. See attached CSS and Statement of Work.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75N95020Q00142
  1. Combined Synopsis
  1. Combined SynopsisCurrentJun 5, 2020

    SARS-CoV2 3CL protease cell-based assay development for drug screening

    Notice 64475df9ce3c4c9590e2b3a925cb1167 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75N95020Q00142

Archive Date

Jun 26, 2020

Office Address

Bethesda, MD, 20892